Haizheng Pharmaceuticals has been granted exclusive marketing rights in 19 provinces in China for micro-core bio-siglet sodium tablets

Accordingly, Haizheng Pharmaceuticals paid a total of RMB 100 million in exclusive licensing fees and no more than RMB 120 million in sales mileage to Microcore Bio.
Chinese mainland exclusive marketing rights for designated regions are granted for a period of 10 years, calculated from the date on which Sigletha sodium is officially licensed for listing from the State Drug Administration (NPMA).
Haizheng Pharmaceuticals will pay a total of RMB 100 million in three exclusive licensing fees to Microcore Bio, the amount of which includes tax.
1) Within 30 working days from the date of the signing of the agreement, Haizheng Pharmaceuticals will pay the first fee of RMB 30 million; 2) within 30 working days from the date when the product is approved for listing by the State Drug Administration, Haizheng Pharmaceutical will pay rmb 30 million in the second fee; and 3) Within 30 working days from the date of the first commercial sale of the product, Haizheng Pharmaceutical will pay rmb 40 million in the third fee.
In addition, during the cooperation period of the agreement, from the date on which the product achieves its first commercial sale, when haizheng Pharmaceuticals' marketing sales amount reaches the sales amount stipulated in the contract, the corresponding milestone event is triggered, and Haizheng Pharmaceuticals will pay the company the milestone fee according to the contract, which shall not exceed RMB 120 million.
agreement cooperation period, from the date of the first commercial sales of products, according to Haizheng Pharmaceuticals in the authorized area of marketing sales, microcore bio will be based on the sales gradient to Haizheng Pharmaceuticals to pay 48%-55% of the marketing service fees.
Sigretamine belongs to a new generation of insulin increasers, is a rigid structure of PPAR PPAR, used to treat type 2 diabetes with poor exercise, diet control, the original innovative drug developed for microcore biology, is currently being reviewed by the National Drug Administration Drug Review Center, is expected to be available in 2021.
。